Suspension of accrual in phase II cancer clinical trials

Yimei Li, Rosemarie Mick, Daniel F. Heitjan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Phase II cancer clinical trial designs commonly incorporate an interim analysis for lack of efficacy. To strictly and ethically implement such designs, one should suspend accrual in cases where pending patient outcomes can affect early termination decisions. This article aims to evaluate various options for accrual suspension and illustrate how the suspension strategy affects operating characteristics of the trial. Methods: We define a strict suspension strategy for determining whether one should continue, suspend, or restart accrual at any point within the trial. The strategy is compared to a naive implementation of suspension and a strategy of no suspension. We evaluate the methods operating characteristics by simulation. Results: The suspension strategy has little effect on type I error, power, and early termination probability. Methods that involve stricter suspension policies generally lead to smaller but longer trials. Differences across strategies are substantial when the ratio of enrollment rate to outcome availability rate is high. Conclusion: The suspension strategy is most relevant in trials that accrue rapidly and require lengthy observation of each subject. The choice of suspension strategy involves a tradeoff between the cost of implementing a potentially complex suspension algorithm in real time versus the cost of enrolling more patients and exposing them to a potentially toxic and ineffective treatment regimen.

Original languageEnglish (US)
Pages (from-to)128-138
Number of pages11
JournalClinical Trials
Volume12
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Phase II Clinical Trials
Suspensions
Neoplasms
Costs and Cost Analysis
Poisons
Observation

Keywords

  • Accrual
  • cancer
  • clinical trial
  • phase II
  • suspension

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Suspension of accrual in phase II cancer clinical trials. / Li, Yimei; Mick, Rosemarie; Heitjan, Daniel F.

In: Clinical Trials, Vol. 12, No. 2, 01.01.2015, p. 128-138.

Research output: Contribution to journalArticle

Li, Yimei ; Mick, Rosemarie ; Heitjan, Daniel F. / Suspension of accrual in phase II cancer clinical trials. In: Clinical Trials. 2015 ; Vol. 12, No. 2. pp. 128-138.
@article{a605056e02c74a3f85c6ff145220c3fa,
title = "Suspension of accrual in phase II cancer clinical trials",
abstract = "Purpose: Phase II cancer clinical trial designs commonly incorporate an interim analysis for lack of efficacy. To strictly and ethically implement such designs, one should suspend accrual in cases where pending patient outcomes can affect early termination decisions. This article aims to evaluate various options for accrual suspension and illustrate how the suspension strategy affects operating characteristics of the trial. Methods: We define a strict suspension strategy for determining whether one should continue, suspend, or restart accrual at any point within the trial. The strategy is compared to a naive implementation of suspension and a strategy of no suspension. We evaluate the methods operating characteristics by simulation. Results: The suspension strategy has little effect on type I error, power, and early termination probability. Methods that involve stricter suspension policies generally lead to smaller but longer trials. Differences across strategies are substantial when the ratio of enrollment rate to outcome availability rate is high. Conclusion: The suspension strategy is most relevant in trials that accrue rapidly and require lengthy observation of each subject. The choice of suspension strategy involves a tradeoff between the cost of implementing a potentially complex suspension algorithm in real time versus the cost of enrolling more patients and exposing them to a potentially toxic and ineffective treatment regimen.",
keywords = "Accrual, cancer, clinical trial, phase II, suspension",
author = "Yimei Li and Rosemarie Mick and Heitjan, {Daniel F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/1740774514562029",
language = "English (US)",
volume = "12",
pages = "128--138",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Suspension of accrual in phase II cancer clinical trials

AU - Li, Yimei

AU - Mick, Rosemarie

AU - Heitjan, Daniel F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: Phase II cancer clinical trial designs commonly incorporate an interim analysis for lack of efficacy. To strictly and ethically implement such designs, one should suspend accrual in cases where pending patient outcomes can affect early termination decisions. This article aims to evaluate various options for accrual suspension and illustrate how the suspension strategy affects operating characteristics of the trial. Methods: We define a strict suspension strategy for determining whether one should continue, suspend, or restart accrual at any point within the trial. The strategy is compared to a naive implementation of suspension and a strategy of no suspension. We evaluate the methods operating characteristics by simulation. Results: The suspension strategy has little effect on type I error, power, and early termination probability. Methods that involve stricter suspension policies generally lead to smaller but longer trials. Differences across strategies are substantial when the ratio of enrollment rate to outcome availability rate is high. Conclusion: The suspension strategy is most relevant in trials that accrue rapidly and require lengthy observation of each subject. The choice of suspension strategy involves a tradeoff between the cost of implementing a potentially complex suspension algorithm in real time versus the cost of enrolling more patients and exposing them to a potentially toxic and ineffective treatment regimen.

AB - Purpose: Phase II cancer clinical trial designs commonly incorporate an interim analysis for lack of efficacy. To strictly and ethically implement such designs, one should suspend accrual in cases where pending patient outcomes can affect early termination decisions. This article aims to evaluate various options for accrual suspension and illustrate how the suspension strategy affects operating characteristics of the trial. Methods: We define a strict suspension strategy for determining whether one should continue, suspend, or restart accrual at any point within the trial. The strategy is compared to a naive implementation of suspension and a strategy of no suspension. We evaluate the methods operating characteristics by simulation. Results: The suspension strategy has little effect on type I error, power, and early termination probability. Methods that involve stricter suspension policies generally lead to smaller but longer trials. Differences across strategies are substantial when the ratio of enrollment rate to outcome availability rate is high. Conclusion: The suspension strategy is most relevant in trials that accrue rapidly and require lengthy observation of each subject. The choice of suspension strategy involves a tradeoff between the cost of implementing a potentially complex suspension algorithm in real time versus the cost of enrolling more patients and exposing them to a potentially toxic and ineffective treatment regimen.

KW - Accrual

KW - cancer

KW - clinical trial

KW - phase II

KW - suspension

UR - http://www.scopus.com/inward/record.url?scp=84924859145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924859145&partnerID=8YFLogxK

U2 - 10.1177/1740774514562029

DO - 10.1177/1740774514562029

M3 - Article

C2 - 25568092

AN - SCOPUS:84924859145

VL - 12

SP - 128

EP - 138

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 2

ER -